Article Details
Retrieved on: 2024-12-18 16:29:48
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Bouncing back from an FDA clinical hold in June, Biomea Fusion's menin inhibitor has shown some early promise in a Phase II study in type 2 diabetes.
Article found on: insights.citeline.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here